Halma plc (HLMA) Earnings Call Transcript
June 13, 2024
Earnings Call Speaker Segments
Good morning, everyone, and welcome to the presentation of our Full Year '24 Results. It's a pleasure to be here and to walk you through another strong set of results. Before we get into the detail of the numbers, I want to take this chance to thank everyone at Halma for the personal contributions each of you has made to our record performance this year. The commitment to delivering our purpose, and the success we've achieved in varied market conditions, is something all of us should be proud of. Thank you. Turning now to the year's highlights. These record results have strengthened our foundations further and increased my confidence in our future growth. We've reported record revenue, along with our 21st consecutive year of record profit. We've delivered healthy revenue and profit growth, both on a reported and organic basis, our EBIT margin and our return on sales were well within our target ranges, we've continued to deliver high returns, substantially above our cost-of-capital, and this, alongside our strong cash generation, which was well ahead of our KPI, has enabled us to make substantial investments to support our future growth. This financial performance supports a further dividend increase, making this the 45th consecutive year of dividend growth of 5% or more.
Overall, this is a strong illustration of our sustainable growth model at work. Steve is going to walk you through our financial results in more detail shortly. Following that, I'll return to offer my thoughts on my first full year as CEO. I'll also examine the pieces of our model that have made this strong performance possible and, even more importantly, leave me confident that we will keep delivering long-term sustainable growth. With that, I'll hand things over to Steve.
Thanks, Marc. Good morning. As you've already heard, we delivered a strong financial performance, with revenue and profit reaching record levels. Given the varied market conditions we've seen during the year, along with other headwinds such as FX and both higher interest rates and tax rates, these results show the benefit of our sustainable growth model — in particular, the advantages of the diversity and breadth of our portfolio, and the agility our operating companies have to act and react. Importantly, these results have allowed us to keep making substantial investments to support future growth, whilst maintaining a strong balance sheet. So let's take a look at the results. I'm pleased that we have delivered good growth and returns. Revenue is up over GBP2 billion for the first time, up a healthy 10%. Adjusted EBIT is up 12%, and EBIT margin at 20.8%, around the middle of our target range of 19% to 23%. Given the increased interest costs from higher interest rates and higher average net debt in the year, adjusted profit before tax is up 10%, resulting in a return on sales of 19.5%, flat compared to the prior year. This is the first full year of substantially higher interest rates, and it remains our objective to absorb these higher costs in the medium-term.
We keep investing heavily to back growth down the road. Our R&D spend came to GBP107 million, equal to 5.3% of group revenue. That spending matters a great deal if our companies are to keep expanding over the medium term. It also mirrors nicely the opportunities our businesses see ahead of them. During the year we completed eight acquisitions — four standalone and four bolt-on — putting close to GBP300 million to work, so we carry on the momentum set by last year's record investment. Marc will walk you through those eight acquisitions later on. Looking ahead, the M&A pipeline stays healthy across all three sectors. It's encouraging too that the acquisitions are adding 5% or more to growth in both revenue and profit. Strong cash generation and a solid balance sheet are what make all this investment possible. So let's examine a few of the metrics behind that. Cash conversion of 103% sits well above our 90% target. We got there through solid underlying control of working capital. Net debt to EBITDA of 1.35 has edged down very slightly even with the heavy investment made during the year. Lastly, we propose raising the dividend by 7% once more. That would mark the 45th consecutive year in which we have lifted it by 5% or more, which again signals how confident we are about the future.
Let's now examine revenue more closely. On this slide, you can see a bridge illustrating the 9.8% year-on-year revenue growth. Breaking down the individual components: organic constant-currency, or OCCY, revenue growth came in at 7.9%, looking at price and volume separately. Roughly 3% of that revenue growth came from price increases. That's above the top end of the 1% to 2% range we typically see. Price cost ran higher in healthcare and also in safety, where we saw annualized benefits along with some of the larger price increases carried over from the prior year. Volume growth of around 5% fell within the historic range, driven by sustained underlying demand and backed by our order intake, which is still running ahead of last year. Acquisitions contributed a solid 5% to revenue growth. Looking forward, it's worth flagging that on the latest currency rates, we'd anticipate an FX headwind of roughly 1% in FY '25. Now let's consider revenue from a different angle — regional destination. This slide presents revenue growth by region. Reported revenue growth appears on the left-hand side, while OCCY growth is on the right-hand side. It's encouraging to see revenue growing across all regions except Asia-Pacific — and let's now focus on the chart on the right, which breaks down the OCCY growth.
In the U.S., which is our biggest sales region, we saw really strong growth. The main driver there was the environmental and analysis sector, E&A, thanks to exceptional growth in photonics. The safety sector also performed well, and that supported growth in the U.S. as well. Growth in Europe and the U.K. was solid and reflected a mix of company performances. In Europe, healthcare was the key driver, with very strong growth in eye health therapeutics. Good performance in the E&A sector also supported this, led by strong growth in the Water Analysis and Treatment sub-sector. Growth in the U.K. was driven by the water subsector as well. In addition, in FY '23, a large public safety contract was successfully completed in the U.K. Underlying growth excluding that contract was over 8%. Asia-Pacific's revenue was 3% lower, reflecting weaker trends in China, partially offset by stronger growth in Australasia. For context, China represents about 5% of Group revenue. If we now move from revenue to profit. This slide shows the year-on-year EBIT bridge. EBIT was above GBP400 million for the first time, up a healthy 12.1% at the reported level and 7.2% on an OCCY basis. This was broadly in-line with the OCCY revenue growth with good margin recovery in safety, which was offset by margin declines in the other two sectors.
In a few moments, I'll walk you through how each sector performed. Now turning to acquisitions: they contributed nicely to EBIT, adding 7.6%. That speaks to the quality of the businesses we've bought recently. Disposals gave us a slight lift of 0.2%. We've completed one more disposal since the year-end, which shows we're constantly reviewing and sharpening our portfolio. Just like with revenue, currency was a drag of almost 3%, driven by Sterling's strength. All in all, it's encouraging that this performance delivered an EBIT margin of 20.8%, putting us in the middle of our target range. Let's move into the sector commentary now, beginning with safety. Safety was a standout performer this year. We had guided that it would bounce back from a difficult FY '23, and it exceeded that expectation. Revenue growth came in strong at 11% and was positive in every region. It also got a solid boost from acquisitions. Europe, safety's biggest region, gained particularly from the Weetech acquisition, completed last year, and from Lazer Safe, which we completed this year. The solid OCCY revenue growth of 6% was also spread fairly evenly across regions and subsectors, backed by a healthy order book.
In the U.S., we had solid growth, and worker safety contributed strongly. Europe and the U.K. posted modest growth, which mirrors a mixed picture in public safety. Asia-Pacific added a strong contribution, reflecting a steady rebound in China after the post-COVID slowdown, plus strong growth in Australasia. Lastly, the smaller other regions contributed strongly, mainly because of the Fire Safety subsector. I was especially glad to see safety's profit margin rise 280 basis points. That came in ahead of what we expected, with an exceptionally strong second-half performance, so it more than recovers the 230 basis points of reduction we saw in FY '23 due to supply chain challenges. The sector gained from good pricing, which — with costs relatively stable versus prior years. It also got further support from portfolio improvements, including completion of a significant ERP upgrade at one of the sector's largest companies. Companies in the sector stayed well-invested to support their future growth. Moving now to the Environmental and Analysis sector. E&A posted very strong reported and OCCY revenue growth of 19% and 21%, respectively. Looking at it by region, growth in the U.S. was very strong.
The standout driver here was the extraordinary expansion in photonics within our Optical Analysis subsector. Demand is accelerating in this business for technologies that enable the transformation of digital and data capabilities. We also got a lift from international growth at our water infrastructure companies in the Water Analysis and Treatment sub-sector. The robust photonics results were partly offset by considerable revenue drops in our high-margin spectroscopy businesses, as we discussed at the half year. The U.K. posted strong growth, with continued expansion at our water infrastructure companies and robust demand in gas detection. Europe delivered good overall growth as well, again with strong demand in gas detection. Asia-Pacific fell 19% on an OCCY basis, reflecting softness in spectroscopy and weaker demand in the flow and pressure control market in India and China. Turning to profitability, the profit margin was down 180 basis points. That mainly reflected the significant revenue decline in the higher margin spectroscopy businesses, especially in the first half. At the half year, we stated that we expected a significant improvement in the sector's profit margin, and that is precisely what we delivered in the second half. The profit margin rose from 20.9% in the first half to a more typical level of 23.7% in the second half.
That gain came from ongoing momentum in photonics and the Water sub-sector. On top of that, spectroscopy got a lift from the cost-base measures we took and from the IT system implementation settling down. E&A kept investing at a solid level, with R&D spend as a share of revenue lower because of a mix effect. We also had good momentum converting the M&A pipeline, with four acquisitions in the year. Now let's move to the healthcare sector. On the whole, healthcare put in a subdued performance, with revenue declining modestly. Acquisitions contributed nicely. It's also great to see momentum continue, with three acquisitions closed in the year. Reported revenue fell 1%, and OCCY revenue was down 3%. Geographically, every region declined apart from Europe, which posted strong growth on both a reported and an OCCY basis. All in all, this mirrored a wide range of outcomes at the subsector level. The majority of our healthcare assessment and analytics companies saw soft demand, a reflection of OEM destocking combined with budgetary headwinds. Inside that subsector, though, analytics and sensors did well, thanks to high patient caseloads and healthcare providers' demand for systems that boost efficiency and patient outcomes.
Our smaller Life Sciences subsector saw a significant slowdown as these headwinds took their toll. Still, our therapeutic solution subsector kept gaining from robust growth in cataract and glaucoma procedures. That is the primary force behind the strong revenue growth in Europe. On profitability, the profit margin fell 70 basis points to 22.7%. That mirrored the effect of weaker volumes, partly offset by solid pricing management and cost discipline throughout the sector. R&D spend rose, reflecting sound investment in new product development, and I'm glad to see sustained high levels of R&D investment backing our medium term growth. Turning now to the group's cash flow performance. This chart sums up the group's cash flows for the year. I'll highlight four key items. Strong EBITDA generation of GBP483 million, up 12%, which is typical for the group and an important element of our sustainable growth model. The working capital outflow improved a great deal, as expected. We're beginning to see companies moderate inventories after the strategic buildup in prior years. In fact, stock turnover got better by nearly one whole turn during the year. That helped cash conversion, which was strong at 103%, and well ahead of our 90% KPI target.
The net acquisition spend reflects the eight acquisitions and the one disposal we made in the period. These acquisitions will become a source of incremental EBITDA in future years. Interest costs increased GBP10.7 million to GBP27.6 million in the year. This was a result of both higher interest rates and high average levels of net debt. Net debt only increased by GBP56 million, despite the strong year for M&A, continued investment in our businesses, and the higher interest costs. As we look forward, we continue to have substantial available liquidity. We have recently extended the maturity of the group RCF to May 2029. In addition, in April, we completed a GBP336 million private placement debt issuance at competitive interest rates. This placement secures financing to meet the group's likely medium-term requirements. Finally, it is worth mentioning that you can find the usual slide in the appendix with our expectations for FY ‘25 in relation to CapEx, the effective tax rate and interest costs. Now let's turn to our financial KPIs and how we performed against them. In my opinion, these are a strong set of results, especially when I consider the varied market conditions and the other headwinds we have faced in the year.
Among the other headwinds are higher interest rates, higher tax rates, and unfavorable FX shifts. On the specific KPIs, I'll keep my remarks to just a few points, since I've already covered several of them. It's encouraging to see solid results on the three KPIs for revenue and profit growth. As for EPS and ROTIC, higher interest rates, higher tax rates, and unfavorable FX shifts all left their mark on both. EPS growth came in at 7.9%, which was respectable but fell short of our 10% KPI. Had those three factors I just named stayed flat, EPS growth this year would have been 5 points greater, at roughly 13%. ROTIC, at 14.4%, stayed high — comfortably above our weighted average cost of capital and inside our KPI range as well. A return at that level, together with the year's strong growth, means the group generated meaningful value in FY '24. Versus last year, our underlying ROTIC performance got better by roughly 40 basis points. Even so, the negative impact of currency, interest, and tax movements more than wiped out that gain. Now let me move to my second-to-last slide. These charts display how the group performed over 10 years at the reported revenue level and at the adjusted EBIT level. To my mind, how consistent that performance has been shows how well our sustainable growth model works.
That covers things like the deliberate diversity and breadth of our portfolio, plus the agility our businesses have to act and react to whatever comes their way. That said, as a team, we're always looking to evolve and move the business forward. And two areas of focus this year have been, first, capital returns. We've tried to sharpen our focus across the whole group. This is partly because of the higher interest rate environment. That focus includes, among other things, an ongoing review of the portfolio, looking at working capital and cash management procedures, reviewing the relevant internal reporting and metrics, and seeking to optimize interest costs. This work is ongoing. Second, metrics and KPIs. We've evolved our metrics and KPIs so they better reflect our strategy and the new environment, and also help with comparison against our peers. For example, at the half year, we started giving prominence to EBIT and EBIT margin and pre-interest growth measures. That has progressed further at the full year. Now to my last slide, which is on guidance. Building on our performance in FY ‘24 and with respect to FY ‘25, we are providing the following guidance. First, we've made a positive start to the new financial year.
Order intake so far this year is running ahead of revenue and also above where it stood during the equivalent stretch last year. For FY '25, we anticipate delivering solid OCCY revenue growth, along with an adjusted EBIT margin near 21%, which sits in the middle of our target range. Lastly, we're well placed to keep making further progress both this year and going forward. With that said, I'll turn things back over to Marc.
Thanks, Steve. So, at the beginning of this part of the presentation, I want to restate the four priorities I established 12 months ago, and I'm glad to say we've made solid progress on them. Organic growth came in above our medium-term trend. On inorganic growth, we enjoyed another successful year for acquisitions. And as Steve mentioned, returns stayed strong and comfortably exceeded our cost of capital. Our continued agility also proved a key asset in delivering that strong performance, and I'll return to that point shortly. Those priorities will stay in place for FY '25, and their delivery will be supported by our sustainable growth model, which keeps us focused on capturing the significant growth opportunities in our markets. Let me now step back and share the key elements that I believe drove our success over the last year. First, our relentless focus on providing value-added solutions to critical customer issues. <<presentation>> To me, these real-life examples of our purpose in action sit at the heart of Halma. They make me really proud to be able to show the difference our companies are making for our customers and for people like us around the world every day, in line with our purpose.
The video also brought out several other things that consistently define our companies. The way they forge tight bonds with customers, which lets them come up with those innovative solutions; the fact that their products can be used around the world; and how, at the portfolio level, they span highly varied end markets, geographies, and technologies. I'll return to several of these points shortly, but first let's look at our purpose in action. In every one of our companies, for every one of our people, our purpose is where everything at Halma begins and ends. That means all of what we do is grounded in taking on some of the major challenges of our era, where solving the problems carries a genuine premium. It brings us together around a shared aim: growing a safer, cleaner, healthier future for everyone every day. It drives each decision we take, it shapes which markets we choose, it draws in ambitious, entrepreneurial people who want to make a difference, and it hands us substantial growth opportunities as we help customers take on some of the biggest challenges of today: delivering healthcare for everyone; coping with the effects of climate change along with growing waste and pollution; and keeping all of us safe in our cities, in public places, and in the places where we work.
Every one of these is a really long-term fundamental challenge, and they're growing larger and more pressing by the day. That, in turn, underpins our growth and returns for decades ahead. Our purpose therefore gives us clarity about what we do and why we do it, while also shaping the major opportunities in front of us. It's within our sustainable growth model that the way we deliver growth is determined. Halma's growth over the last 50 years has been supported by the principles that now make up our sustainable growth model. That model has been tested and proven across a wide range of environments — both good and challenging — over many years. This year was no exception, and our performance has reinforced still further my confidence that the model is fundamentally fit for the future. As I've said before, it matters that we keep challenging ourselves to make sure the model stays relevant, and to refine and optimize it as our circumstances change and we carry on scaling. And across the last 12 months, I've tested it with our company leaders. Whether that was at our annual Accelerate leadership event, at our talent development programs, on our regular MD calls, or during my company visits, where I visited the majority of our companies across eight countries to see our model in action firsthand.
I've put a question to our leaders: in what ways can Halma best help your company grow over the long term? And together with our leadership team, I've also thought about what allows us to produce resilient growth and returns across market cycles. For me, there are three key takeaways. First, we have to maintain a portfolio. It's not only aligned with our purpose and strategy, but also remains highly diverse. Second, as we grow, we need to retain agility, making sure that our organizational model gives our people the autonomy to respond quickly to opportunities and challenges. And third, talent and culture are critical. We want to recruit, retain, and grow great people. It's crucial that in our decentralized model, we have the very best people empowered to make agile decisions close to our customers. So, let me take each of these in turn, outlining the actions we're taking to make sure that we're best positioned for the future. Turning first to our portfolio, we currently have nearly 50 companies. And as well as being unified by a purpose, they share a number of common characteristics. For example, they operate in high value market niches, their markets have global potential and high exposure to long-term growth drivers. But as a portfolio, they're also highly diverse, whether that be by sector or end market, by geography, by technology, or by distribution channel.
So it sounds a bit paradoxical: even as we concentrate on a handful of major challenges, we remain a very diverse organization. Let me make that concrete with a few examples showing how we stay focused on those particular long-term challenges while keeping our diversity. Take climate change first — there we have major opportunities to deploy a broad range of technologies across many different end markets. Consider just one of those end markets, wind farms, where we've put money into technologies that guarantee safe access for workers via businesses such as Sentric and Fortress, and that check infrastructure integrity, for instance using deep trekkers remotely operated underwater vehicles to inspect offshore wind farms. As another illustration of how we assist customers in addressing the challenge of water conservation, you've already seen in the video some of our freshwater work through companies such as HWM. We're also seeing considerable growth opportunities in helping customers safeguard the integrity of ageing wastewater infrastructure. We've been investing organically via existing companies, such as Minicam with their pipe crawlers shown here, and also through M&A to broaden further our technical capability and our distribution reach, with two acquisitions made in FY '24. Still on water, we also hold a long-standing capability in water testing through Palintest, which we acquired in 1983.
At present, that translates into over 250 million tests annually across a broad customer base. I take special pride in the fact that more than 5 million of those tests serve partners working in international relief and development. As a last illustration, consider healthcare, where we tackle the difficulties from two directions. One centers on the patient, the other on healthcare providers. Our technologies aimed at patients enhance quality of life, targeting the long-term problems tied to chronic illness. We operate across a broad set of end markets, including areas like eye health as well as respiratory and circulatory functions. Just as in other end markets, we do this via a group of companies holding strong positions in particular niche markets. Illustrations include Medicel, which we featured in the video, Volk in eye health diagnostics, as shown here, plus Keeler, MST, and SunTech. Our second focal area is healthcare providers, assisting them in boosting efficiency within healthcare facilities or improving the quality of care. PeriGen stands out as an excellent example here, thanks to its technology that safeguards mothers and their unborn babies. It leverages artificial intelligence to deliver an automated early warning platform during labor, which lets healthcare professionals devote more time to direct patient care while attaining better clinical outcomes.
Those are just a handful of the many strong examples I could offer to try to bring our impact to life. So, our growth and resilience through the cycle is supported by the long-term growth drivers in our company's markets, and then at a portfolio level, it's further underpinned by the diversity and breadth of our companies. And each year, we enter new markets and add new capabilities through acquisitions, which further increases our opportunities for growth and adds even more diversity. Let's take a look at what we've added in FY '24 through our M&A activity. It's really pleasing to report another strong year for acquisitions, building on last year's excellent momentum. In fact, we've spent more on acquisitions in the last two years than in the previous five. As you heard from Steve, we spent close to GBP300 million in FY ‘24 on four standalone companies, spread across all three of our sectors and four bolt-ons to accelerate our new product development and expand our distribution. And we've made a good start to FY '25 with one further acquisition completed, namely MK Test. And these acquisitions have further strengthened our positions in some exciting markets with growth underpinned by long-term growth drivers.
Take electrical testing with MK Test, for instance, and women's health — a market that has historically been underserved — with Rovers. We've also kept our geographic spread intact, purchasing businesses across the U.K., Europe, the USA, and Asia-Pacific, while always making sure our decision-making stays disciplined. Every one of those companies delivers on our purpose, operates in a niche market backed by long-term growth drivers, fits our culture, and satisfies our financial criteria. That same discipline gets applied right across the whole portfolio. It's what produced two small disposals: FireMate in FY '24 and Hydreka in FY '25. All in all, I'm genuinely pleased with how our M&A momentum is going. Our pipeline is healthy and holds well over 600 companies, each one aligned with our purpose. It consists mainly of SMEs operating in markets that are the same as, or adjacent to, those of our existing companies. That means we can keep delivering strong M&A in line with our financial model by completing a number of smaller acquisitions annually. We've put investment into our teams over recent years too, which further strengthens our M&A expertise within our sector teams, at the divisional level, and inside our companies. Financially speaking, as Steve has told you, we hold a strong balance sheet, substantial committed financing, and very healthy levels of cash generation.
That mix of a strong pipeline, solid capabilities, and financial strength is exactly what makes me confident we can keep identifying and buying outstanding businesses that will drive our growth going forward. Moving to my second point: making sure we stay nimble as we get bigger. Our organizational structure lets each of our companies act with the speed and opportunism of a startup while still enjoying the benefits that come with belonging to a FTSE 100 global group — something Kathy captured perfectly in that quote. Whenever I visit our companies, I encounter leaders who aren't sitting around waiting for instructions from the group level; they operate entrepreneurially, aware that they have the authority to grab the opportunities their markets present, while also being held accountable for delivering against clear medium-term financial targets. We want them kept close to customers, suppliers, and their markets, so they can make the wisest choices for their business as those markets change. Meanwhile, we provide them with the advantages of membership in Halma — the scale we offer as a group, our collaborative culture, through which they draw on the experience, backing, and best practice of sibling companies, the capacity to recruit even stronger talent than they could alone, the support delivered via our menu of growth enablers, and access to specialist expertise and knowledge in fields like digital technology, M&A, talent management, and international expansion.
We’re also able to back them with capital, which lets them put money into growth opportunities with confidence—ones that fit each company’s own long-term growth strategy. And that mix of agility plus support when it’s needed is genuinely powerful for our businesses in their niche markets. Let me make that concrete with a few examples of how our companies gained from that agility in FY ‘24. Take HWM: it doubled production capacity to satisfy demand from U.K. and U.S. water companies for its leak detection devices. That was done at pace and with limited investment by reorganizing production lines and creating new testing software. Sentric, one of our interlock companies, launched a new global distributor platform after studying best practice at another Halma company. Orama acted quickly after a regulatory change for large timber frame buildings in San Francisco, making further use of the temporary fire detection technology you saw in the video being used in France. Thermocable, one of our fire detection companies, is reaching new markets in tunnel and industrial safety in India by partnering with another Halma company; NovaBone is rapidly raising output of synthetic bone graft material after success in China with volume-based procurement; and Crowcon is pivoting its gas detection technologies into the battery energy storage market.
Yet none of that could happen without the remarkable individuals and leaders we have here. Now let me explain how we find, keep, and develop the very finest talent at Halma. Because our decentralized structure depends on outstanding leaders—people driven by a sense of purpose—who are able to run every business as though they owned it, and who demonstrate the kind of agility and collaborative outlook I described a moment ago. Much like the businesses we build and buy, there are key shared traits we look for in the individuals we bring on board: strong intellect combined with sound judgment; the ability to learn quickly and room to grow; and a solid cultural match. Indeed, talent matters so much to how we operate and to what we achieve that we have laid out the core principles within our own talent philosophy, which you can view on the slide. Bringing in individuals with strong ambition and potential also builds an internal pipeline of leaders capable of stepping up to run our companies down the road. To offer another single illustration, drawn from our leadership development program—designed for high-potential people who aren't yet serving on company boards—in FY ‘24, 11 participants were promoted onto company boards, and 2 of those moved into company MD roles.
It’s just great to see that. So let me go back to where I started. A mix of several things powers what we’ve achieved: our purpose, which is clear and positive, guides our decisions and shapes which markets we choose; a varied set of businesses, every one of them competing in niche markets and supported by strong long-term growth drivers; the agility that is built into our model; and the outstanding people within our companies together with their leadership teams. And once I weigh how big the opportunities are that lie ahead of us, in markets we already serve as well as new ones, I feel genuine excitement about what’s coming. Those opportunities sit alongside the difficulties we all know from daily life: climate change; clean water and air; access to healthcare; keeping people and assets safe. And here at Halma, we possess the capabilities to assist our customers in tackling these difficulties — the people, technologies and financial resources required, plus the organizational capability and agility to deliver. And that is exactly what gives me confidence that we will carry on our track record of delivering sustainable growth for decades to come. That brings the presentation to a close. And now we have a bit of time for questions. There are two ways to ask a question. Either raise your hand with the tool at the bottom of your screen and I will invite you to ask verbally, or type your question in, and Steve and I will read it out and then respond.
Alright, our first question comes from Jonathan. Jonathan Hurn? I believe you have to unmute yourself there, Jonathan. There we go.
Is this coming through now?
Morning, Jonathan.
Thanks. Yeah, just a couple of questions, if I may. The first one is on Environmental and Analysis. I was wondering whether you might expand a bit more on photonics, so to speak. Clearly, there was strong growth last year. How much longer can that cycle keep going? Do you believe that the momentum in photonics, especially in the U.S., can last through the whole of next year? And related to that, just on spectroscopy — I mean, what are your thoughts there? When do you think you might begin to see, or expect to see, that market recovering, please?
Sure, I'll take that one, Jonathan. And on the broader photonics topic, I think it's worth framing it against, obviously, a robust group result, with revenue and profit both rising 8% on an organic constant currency basis. And as I mentioned during the presentation, that improvement has shown up right across the whole portfolio, which really speaks to the diversity we hold within it. And once more, for context, to borrow a line from Steve in the presentation, safety was the standout, turning in year-on-year profit growth of more than GBP39 million. And again, for context, that sits alongside GBP19 million in optical analysis within the E&A sector. That being said, it's still a tremendous contribution and a genuine effort, and again, it comes back to how agile the teams have been this year in scaling up to a really strong opportunity there. I'm really pleased with the growth delivered. And looking across the broader portfolio, we've seen several companies scale up successfully this year. So I discussed HWM in the presentation, and Medicel featured in the video as well, so it returns once more to that portfolio point. That being said, I'm really pleased with photonics growth this year.
Looking ahead, we have a lot of confidence that FY '25 will bring another strong contribution. Beyond that, I think the focus is really on what opportunities photonics opens up for the broader group, and that's something we'll be exploring as we go forward. So we're very happy with what it's delivered — the teams did a great job scaling it up. Turning to spectroscopy, we did see some benefits in the second half from the self-help measures and the actions taken during the first half of the year. So, to go back to that portfolio agility point, you have one piece of E&A scaling up strongly while another piece takes the right actions. We saw the benefits from that. On demand and looking ahead, order intake has started to return, and there are certainly pockets of good momentum in order intake. Still, I think calling it a recovery would be premature. So in how we're thinking about spectroscopy, we are seeing a recovery come through in the second half.
Thanks, that’s clear. One more question, and it’s plainly about your margin guidance: roughly 21% EBIT margin this year compared with 20.8% last year. Clearly you’re seeing solid earnings growth, and I’m saying that with respect to the outlook. Why isn’t the gearing stronger on that margin for this year? Is mix the reason? Is something effectively working against you when it comes to achieving a bigger margin improvement?
I'll handle that question, Jonathan. What we're looking at is genuinely a mixed picture. So, margin performance should improve in some areas—especially E&A, given how tough its first half was. Still, the overall dynamic is mixed. You saw safety's margin bounce back strongly in FY ‘24. From safety in FY ‘25, I wouldn't anticipate much margin expansion. E&A should show some improvement. And then there's healthcare, which we described as delivering a challenging performance in FY ‘24. Recovering will likely take some time—probably at some point in the second half. But we'll have to wait and see.
Thanks a lot, everyone. That’s very clear. Thank you.
Thanks, Jonathan. I see Rory has a hand raised, so let’s go to Rory.
Hello, and good morning.
Morning, Rory. Everything’s clear on my end.
Understood. Excellent. Thanks for taking my question. Congratulations on a solid set of results and a strong outlook. I have no doubt that the 9% share price appreciation this morning stems from that broad strength across the group, along with that profitable growth and safety. That said, I do want to return to the photonics point, if I may, and really just ask: how do you view your ability to grow share in that space, where I suppose customer concentration has been quite high there historically? Do you think that could be something that, that business might look at? That's the question. Thanks.
Sure, absolutely. Rory, within the group we've had photonics businesses since — well, definitely 2010 and earlier, and we're always on the lookout for a range of opportunities; a core part of that business still operates across a lot of different end markets. So we certainly look ahead with excitement about other areas where we can apply that technology to address some of those challenges I mentioned around our purpose. We've got solid capability, and it's then a matter of seeking out those applications. So I'm confident about the opportunity ahead. I really do think that what we've delivered over the last 2 years is a tremendous illustration of how we can bring in genuinely strong capability, terrific local teams, and then, with the group's backing, give them the ability to compete in these markets and with these kinds of customers. So it's a really good illustration of what we're trying to achieve here in the group when it comes to delivering future value.
Thanks. Appreciate it. Could I squeeze in one quick follow-up? Still on E&A — it seems like the U.S. has seen solid growth in water as well, and clearly the video hinted at that. I'm just wondering how structural that water growth in the U.S. really is. Thanks.
Yeah. Without a doubt. The video mentioned regarding how massive the water infrastructure and the network are, and of course, the aging pipes across the U.S. So we view that as a solid market for us. We believe we have the technologies, and we have proven capability. We already have a good footprint in the U.S. when it comes to water, and it's definitely an area that excites us as we look ahead.
Yeah, I'll just build on that. If we break down the water subsectors, the U.K. makes up roughly 36% of the business, while the U.S. accounts for around 25% of those subsectors. So I'd say there's plenty of room for us to expand in the U.S.
Excellent. Thank you so much. Congratulations once more.
Let me take a couple of the questions that came in typed. The first is from Stefan. Could you — apologies, my screen has just gone a bit blank on me. Could you explain the reasoning behind the divestment of Hydreka? And his second question asks for a bit of color on photonics as we head into H1'25. H1 was good, but demand came through much more strongly in H2. And do your assumptions factor in an improvement? I believe we've addressed most of that, but Stefan, please speak up if we haven't covered the photonics question. Then, coming back to Hydreka, just to add a little context from the presentation, we said we're always seeking to refine the portfolio. These are small portfolio refinements, so taking Hydreka out gives you scale — it's roughly EUR9 million of revenue. That said, the real driver was Hydreka's financial profile, which sits below that of a typical Halma company, both in terms of revenue growth and return on sales. But the fundamentals behind that were the growth strategy, and the strength it has going forward is very much a rental model that is specific to France.
A big chunk of their business today, and where future growth could come from, involves selling products from third parties. So going forward, it simply didn't meet our criteria. And we wish the team well with their new owner. So, I see David Farrell has his hand up, so we'll go to David.
Morning, and thanks to you both. I have a brief question about E&A, though it isn't really focused on photonics. I'm looking at R&D as a share of sales there, and Steve, you mentioned that revenue mix plays a role in that. Could you expand a little on what has pushed that figure down? As I recall, E&A is likely among your less regulated segments, so it would normally carry a higher R&D level to support the ongoing profit and revenue growth opportunities.
Hello, David. This is Steve speaking. You've hit the nail on the head regarding mix. The reason is that revenue accelerated so much over the year—especially in photonics and water infrastructure—that our R&D spending failed to keep pace with it. So this is a mix effect, and it does not signal any reduced confidence or fewer opportunities in E&A ahead. In fact, quite the opposite: we view it as a very promising group of subsectors and long-term end markets. Therefore, it's purely a mix effect, and nothing else.
Alright, thank you. My second question concerns M&A and the deal pipeline you mentioned. I think 2024 was somewhat a continuation of 2023, when you were acquiring businesses whose return on sales was well above the group level, which looks as though it represents something of a shift versus history (ph). As you look at the pipeline ahead, do you expect that mix to keep moving in the same direction it has, or is it still quite a wide range of opportunities we're looking at?
It's quite a wide spectrum, David. Naturally, the starting point ties back to our purpose—seeking out companies in those niche markets that address high-value problems while benefiting from long-term underlying growth drivers. So we're consistently evaluating high-quality businesses that typically demonstrate strong growth and strong metrics. We're genuinely pleased with the ones we've managed to identify. It's not as though we sit here saying we must locate businesses with a higher return on sales, but that's a very solid starting point. Actually, when I review M&A deals, my attention leans more toward gross margin. In other words, what value are we delivering to our customers, and which problems are we solving? And we've been truly encouraged by what has come through, and we feel confident about the pipeline ahead in that regard.
All right, thank you so much.
And David, building on what you said, I think it’s important to point out that especially during those initial few years when we bring those businesses into the group, we ultimately do put investment into them—whether that means bolstering the Board of Directors, the financial governance, or putting capital and resources into the operations. So they come in as very growth accretive and will be very growth positive, but we also invest during those first few years.
Thanks, Steve.
Yeah, thanks.
All right, and now I’ll hand things over to Max. Max Yates.
Thanks. Am I coming through okay?
Absolutely, Max, we're able to do that. Yeah. Morning to you.
Morning, everyone. So, first question only, since I've already heard (ph) this from a few people this morning. To the best of your ability, could you really spell out precisely what's going on in the photonics business? Maybe reference exactly which customer groups are driving this. Is it data centers — that's something I've been asked a few times. So as much as we can discuss the end customers, it would be really great to get some color, in really simple English, on exactly what's happening there.
I'll definitely give that a try, Max. First off, I should say that everyone familiar with these markets understands how fiercely contested they are. On top of that, when you work at that end of the technology, a great deal is kept confidential. As a result, there are limits on how much detail we can share. Having said that, we've discussed before — and to offer some clarity on where we compete — it centers on photonics and the technologies that underpin the development of digital and data capabilities. That, in our view, is a growth area. But, as I mentioned, and as you'll understand, competition is intense and confidentiality is significant. So I really can't go any deeper than that.
That's useful, thanks. And maybe one for Steve as well. Clearly, cash conversion has been very, very strong this year, coming in above your targets. And I suppose, looking at working capital across the group — I know it will vary somewhat by business — do you see opportunities to bring inventories down and improve working capital when you look at the group in aggregate? And could we see that kind of cash conversion, above your 90% target, carrying on into 2025?
Right. Thanks, Max. So, like I mentioned in the presentation, capital returns is something we've been concentrating on, and I'm happy with how far we've come over the year. I'm glad you highlighted that — it's 50 businesses managing their working capital and deciding what they need to do with the capital they employ. That said, it's been really encouraging to watch inventory levels in absolute terms come down somewhat year-on-year even though the group has grown. And seeing stock turns improve by nearly a full turn this year was genuinely good to see. Do I think inventories will keep falling? That's hard to predict, I'd say, since it depends on what the businesses are seeing ahead of them. What I do anticipate is a sustained emphasis on return on capital employed, and for that to take steps forward. That said, it remains a work in progress. We've had plenty of discussions across the group in a very Halma way — there's no central diktat, it's simply about raising awareness and building understanding of what's needed and what's required. So, I think it will progress in FY '25.
On cash conversion, I do see us running ahead of the 90% target. I wouldn't want to commit to how far ahead of it, but I think that's our expectation.
All right, that's great — many thanks.
Thanks, Max. Then over to Bruno. Bruno, I believe your line is muted. There we go.
Thanks for taking the question. So I want to focus on photonics, because if I go back to E&A, with 32% organic sales growth in H2, and given there were some headwinds in other businesses, I would have thought photonics likely grew 50% or more during the second half. Could you clarify how much of the H2 growth came from the photonics business? And on that strength, was it two or three non-repeat orders, or was it broad-based — more a flurry of orders that you executed on? I'm really just trying to get a sense of how useful H2 is as an underlying indicator of demand. Is this sustainable? Should we be annualizing this number when we think about 2025? Any color here would be useful.
Okay, thanks, Bruno. Obviously there have been plenty of questions about photonics today, so I want to return to the wider portfolio point. That is what produced our result this year — the growth we saw in safety, the performance across a number of our companies. And that isn't unusual. Looking back across the last 20 half years, meaning over the last 10 years, only four half years have seen every sector increase its profit simultaneously. So we remain, and always have been, very much a portfolio of 50 fantastic companies, each contributing to our long-term growth. That said, returning to the photonics specifics, we did see good growth in the second half of the year. Again for context, the optical analysis sector — that subsector in total — gave us profit growth of over GBP19 million across the year. To put that in context, our fire safety businesses gave us GBP24 million of profit growth across the year. On your point about how that carries forward, as Steve said earlier, we are confident about that demand continuing.
We really view that as an acceleration and phenomenal growth during the first half, which has produced a good level of performance in the second half—and we see that continuing through FY '25.
Understood. So it seems like something that shouldn't reverse as we head toward 2025. All right. And then, I suppose, changing topics, since I believe you brought up healthcare — you're expecting a recovery in H2 — and spectroscopy should also recover somewhat in the second half of fiscal 2025. I guess, any color on seasonality as we consider 2025. Would you expect a normal shape, or should it be weighted more toward H2 given those points?
I'd say, Bruno, that this year the weighting will actually lean more toward the first half. If you take what Marc mentioned about the first half regarding E&A and photonics, we achieved a high contribution level in the second half of this year, and we'd expect that level to carry through both halves of next year. So on that basis, since the first half of last year was weaker, you'll see substantial growth in the first half, though less in the second half, which will be flatter. I think that's part of the shape — it will drive how next year takes shape. On healthcare, yes, I'd like to believe we'll see some improvement in the second half, and that will aid the second-half performance. But taken as a whole, I think the growth shape across the two halves will probably come in at roughly 48 to 52 overall in terms of profitability.
Thanks, Steve.
Understood. Regarding orders, we’re off to a solid start this year, though I wanted to ask whether order intake has a seasonal pattern. Is it normal for orders and book-to-bill to come in stronger during the first quarter, or is that not how it works and this is simply a better fiscal Q1 for you?
No, it isn't seasonality. There is a bit of seasonality, since E&A is a business that's more weighted toward the second half, but taken as a whole, the group isn't driven by seasonal patterns. So we head into FY '25 with a healthy order book, and as we've said before, order intakes and book-to-bills sit above one, and our order intakes are running ahead of last year's. All of that supports the guidance we've provided: good OCCY revenue growth in FY '25, with a solid margin at around 21%.
Understood. Regarding the order book, I believe you said earlier—or at least during H1—that it stood 30% to 40% higher than historical levels. What's the position now?
Yes. If I put it in terms of weeks, Halma has traditionally run at 8 to 10 weeks. Right now we're slightly above that level, but what we encountered going into FY ‘24 was an extremely elevated order book. Customers were placing plenty of orders well ahead of time since they were worried about supply chain problems and so on. What has happened — and we discussed this at the half year — is that it has been normalizing as the year has gone on. So overall we're still somewhat higher than usual, yet we do view the market as much more normalized and much more normal generally. So, we believe the market has largely reached equilibrium, and we're just above 1 on book-to-bill, and the order intakes are backing up the underlying revenue guidance.
Understood — thanks a lot.
Thanks, Bruno. I’m not seeing any other hands raised, so if you want to ask something, please raise your hand now. No? Okay, and there are no open questions. Bruno, just to be clear, your hand is back up — is that because you have a follow-up question, or is it just a hangover?
No, I have a follow-up. I'd like to ask — let's return to the queue since I figured others might have questions. But could we discuss pricing for a bit? Because I believe at the start of this fiscal year, you were talking about price increases, or roughly 1% to 2%. You delivered 2% in H1. The contribution in H2 appears to have been 4% or near that. So it looks like you implemented some sequential increases during the year — was that within particular sectors or business areas? And could you also address what you expect for 2025 regarding pricing?
Yes, that's fair. We did move into the 1% to 2% range, and our result has landed a bit above it. Strong pricing came through in safety, and we saw solid pricing in health care too. That is what has shown up. As we look across the 50 businesses — and it is always worth remembering that those 50 businesses set their own pricing, since they sit closest to their markets and their customers — we regard 1% to 2% as typical Halma levels. For FY ‘25, we expect to land in the region of 1.0% to 1.5%. That reflects our current thinking, and it is what supports our guidance.
Understood. And then one last item on life sciences — did you mention earlier that you're noticing some tentative signs of a recovery? And I suppose regarding your life sciences business in China, or China more broadly, could you describe a bit what you're observing in that end market, and whether expectations of stimulus — or at least talk of stimulus — is having any influence on your end customers, or how you think that will play out over the next fiscal year?
Yeah. I think it's reasonable to say that, at least when we look at spectroscopy, we are seeing some spots of order intake returning. But like I mentioned, Bruno, calling that a recovery feels premature to me. We're definitely looking at our forecast pointing to something near the second half. Then, zooming out a bit more to China — again, just for a bit of context — roughly 5% of group revenue was down 6% across the various sectors. But as always with Halma, it was quite mixed. We had some strong performances. And in particular, again, within our safety sector, they've delivered a good performance in China. The difficulty was in spectroscopy, and certainly in some of those other end markets we're exposed to beyond life sciences — consumer electronics, testing, etc. So again, too early to call in terms of that recovery. It certainly feels like we've reached the bottom, but I wouldn't want to claim it's bouncing back faster, and certainly we're very much looking toward the second half.
Got it. Thanks so much.
Thanks, Bruno. Stefan, I notice your hand is raised.
Yeah, hello, Stephan from HSBC. Thanks for taking my question, and thanks for answering the written ones I sent earlier. Just on the portfolio management side, I appreciate that you're obviously looking into refining the portfolio to bring through more of the Halma characteristics and make them pronounced across most of the portfolio — you have that. And that's for Steve, if you look into the portfolio, is there a percentage — I mean, how should we think about it? Is there a percentage that is close to not making the Halma criteria, where you'd have a closer look? In other words, should we expect more divesting — more divestments going forward? Should we expect more portfolio measures to get the returns back as well to — I mean, you have good returns, but back to a more pronounced level?
No, we have reviewed the portfolio, and reviewing it is something we do continuously. So I would not want to create the impression that, for instance, the incoming CFO or the incoming CEO has arrived and that we are now examining the portfolio in some manner we never did previously. Reviewing the portfolio and seeing what is in it is something we do all the time. When we examine businesses, we examine them with a long-term view. So some businesses in the portfolio will always be declining, and they might decline for a year or two. And whenever we see that, we try to understand what lies behind it. Is it a market issue? Have we lost market position? Has there been niche erosion, or is this a transitory point that they will work through? Is there a management issue, and maybe it is a management issue? So at the moment we are not looking at the portfolio and still saying there is a big slug that needs changing or a big churn that needs to happen. But we review it constantly. So I would not be, sort of, disclosing that here is a percentage of businesses. What we are really doing is still asking, can we see the long-term prospects for that business?
Will it meet Halma's traits over the long term? If it does, that's the kind of business we want in the portfolio, even if we have to work through a brief stretch of challenge?
So what you're telling me is that, right now, you're pleased — really pleased — with how the portfolio stands?
Yeah. And based on the results we just released, I believe that backs it up.
Great, thank you.
Thanks, Stephan. So there aren't any further written questions and no hands raised, so let's give it one final opportunity for anyone. Alright, that means all that's left is for me to express a big thank you to everybody. I appreciate the questions, and have a great day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Halma plc transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Halma plc earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.